7151-76-0 Usage
Description
4-(Methanesulfonylamino)benzoic acid, a chemical compound with the formula C8H9NO4S, is a white crystalline solid. It features an aromatic benzene ring with a carboxylic acid functional group and a sulfonamide group. 4-(METHANESULFONYLAMINO)BENZOIC ACID is recognized for its potent inhibitory effect on carbonic anhydrase, making it a significant pharmaceutical intermediate in the synthesis of various compounds and a valuable research tool in drug development.
Uses
Used in Pharmaceutical Industry:
4-(Methanesulfonylamino)benzoic acid is used as a pharmaceutical intermediate for the synthesis of other compounds, leveraging its structural properties to create new therapeutic agents.
Used in Carbonic Anhydrase Inhibition:
4-(Methanesulfonylamino)benzoic acid is used as an inhibitor of carbonic anhydrase for its potential therapeutic applications, particularly in the treatment of conditions such as glaucoma, where the inhibition of this enzyme can help reduce intraocular pressure.
Used in Drug Development Research:
As a research tool, 4-(Methanesulfonylamino)benzoic acid aids in the development of new pharmaceuticals by providing insights into the structure-activity relationships of carbonic anhydrase inhibitors and other related compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 7151-76-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,1,5 and 1 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 7151-76:
(6*7)+(5*1)+(4*5)+(3*1)+(2*7)+(1*6)=90
90 % 10 = 0
So 7151-76-0 is a valid CAS Registry Number.
InChI:InChI=1/C8H9NO4S/c1-14(12,13)9-7-4-2-6(3-5-7)8(10)11/h2-5,9H,1H3,(H,10,11)
7151-76-0Relevant articles and documents
Convenient synthesis of primary sulfonamides
Greenfield, Alexander,Grosanu, Cristina
body text, p. 6300 - 6303 (2009/04/06)
An efficient protocol for a one-pot synthesis of mono-sulfonamides has been developed. It features utilization of excess of sulfonylating agent followed by base mediated recovery of the primary sulfonamide.
Compounds useful as reversible inhibitors of cysteine proteases
-
, (2008/06/13)
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
Substituted benzene derivatives useful as neuraminidase inhibitors
-
, (2008/06/13)
A compound of the Formula (I): STR1 or pharmaceutically-suitable salts or prodrug forms thereof, wherein: n is 0-1; m is 0; p is 0-1; R1 is --CO2 H; R2 is selected from the group consisting of H, --OH, and --NH2 ; R3 is H; R4 is --C(O)NHR8 ; R5 is --NHC(R6)NH2 R6 is selected from the group consisting of =NH, =NOH, =NCN, =O, and =S; and R8 is selected from the group consisting of C1 -C4 linear or branched alkyl substituted with 0-3 halogens on each carbon.
